Spero Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview

Spero Therapeutics

08/11/2024 15:49

* Spero Therapeutics Inc  SPRO.OQ   SPRO.O  is expected
to show a
fall in quarterly revenue when it reports  results on November
14 for the period ending January 1 0001
    * The Cambridge Massachusetts-based  company is expected to
report
a 69.9% decrease in revenue to $7.667 million from $25.47
million a year ago, according to the mean estimate from 3
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Spero Therapeutics Inc
is for
a loss of 36 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Spero
Therapeutics Inc is $5.00​, above​ its last closing price
of $1.31. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -0.34       -0.38      -0.33     Beat    13.2
 Mar. 31 0001  -0.04       -0.04      -0.24     Missed  -453.9
 Dec. 31 2023  -0.23       -0.10      0.96      Beat    1,060​
 Sep. 30 2023  -0.02       -0.03      0.04      Beat    233.3
 ​​Jun.        -0.33       -0.34      -0.23     Beat    33
 30 2023                                                
 Mar. 31 2023  -0.33       -0.33      -0.25     Beat    25​
 Dec. 31 2022              0.04       0.55      Beat    1,169.
                                                        3
 Jan. 1 0001   -0.31       -0.30      -0.33     Missed  -8.8
 This summary was machine generated November 8 at 15:48 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)